Symbols / MNOV $1.47 +0.68% MediciNova, Inc.
MNOV Chart
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Fundamentals
Scroll to Statements| Market Cap | 72.36M | Enterprise Value | 41.76M | Income | -12.00M | Sales | 409.66K | Book/sh | 0.84 | Cash/sh | 0.63 |
| Dividend Yield | — | Payout | 0.00% | Employees | 6 | IPO | — | P/E | — | Forward P/E | -3.54 |
| PEG | — | P/S | 176.62 | P/B | 1.74 | P/C | — | EV/EBITDA | -3.15 | EV/Sales | 101.94 |
| Quick Ratio | 8.11 | Current Ratio | 8.16 | Debt/Eq | 0.51 | LT Debt/Eq | — | EPS (ttm) | -0.24 | EPS next Y | -0.41 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-13 | ROA | -16.36% | ROE | -25.50% | ROIC | — |
| Gross Margin | 7.58% | Oper. Margin | -20.38% | Profit Margin | 0.00% | Shs Outstand | 49.22M | Shs Float | 42.26M | Short Float | 0.48% |
| Short Ratio | 2.78 | Short Interest | — | 52W High | 1.96 | 52W Low | 1.17 | Beta | 0.61 | Avg Volume | 63.47K |
| Volume | 11.35K | Target Price | $9.00 | Recom | None | Prev Close | $1.46 | Price | $1.47 | Change | 0.68% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$1.47
Latest analyst target
3. DCF / Fair value
$-2.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.47
Low
$6.00
High
$11.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-16 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2026-01-30 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-12-18 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-12-08 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-11-04 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-31 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-08-27 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-07-24 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-06-16 | main | B. Riley Securities | Buy → Buy | $5 |
| 2025-04-09 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-14 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-21 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-12-06 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-12-02 | init | D. Boral Capital | — → Buy | $9 |
| 2021-03-10 | init | Maxim Group | — → Buy | $15 |
| 2020-03-13 | main | B. Riley Securities | — → Buy | $11 |
| 2018-03-28 | init | B. Riley Securities | — → Buy | $22 |
| 2012-05-24 | main | Ladenburg Thalmann | — → Buy | $11 |
- MediciNova (NASDAQ: MNOV) to vote on 147M share increase, director slate - Stock Titan Mon, 20 Apr 2026 21
- MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill Fri, 17 Apr 2026 07
- symbol__ Stock Quote Price and Forecast - CNN Sat, 09 Mar 2024 17
- D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - MSN Sun, 12 Apr 2026 09
- MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ - Stocktwits Fri, 31 Oct 2025 07
- 3 Penny Stocks With Market Caps Over $80M To Consider - simplywall.st Mon, 03 Nov 2025 08
- MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat Mon, 23 Mar 2026 07
- MediciNova Inc stock draws attention amid biotech pipeline momentum and analyst upside calls - AD HOC NEWS Fri, 20 Mar 2026 07
- MediciNova reports preliminary 2025 financial results in Tokyo filing - Investing.com Fri, 20 Feb 2026 08
- Maxim Group Reiterates "Buy" Rating for MediciNova (NASDAQ:MNOV) - MarketBeat Mon, 23 Mar 2026 07
- This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga Mon, 16 Mar 2026 07
- MediciNova (NASDAQ: MNOV) publishes tipelukast data: MN-002 enhances cholesterol efflux - Stock Titan hu, 30 Oct 2025 07
- Medicinova Stock Price Forecast. Should You Buy MNOV? - StockInvest.us ue, 01 Dec 2020 17
- What is the current Price Target and Forecast for MediciNova (MNOV) - Zacks Investment Research hu, 06 Oct 2022 17
- MNOV Stock Price, News & Analysis - Stock Titan hu, 24 Apr 2025 23
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.41
|
0.00
-100.00%
|
1.00
|
0.00
|
| Operating Revenue |
|
0.41
|
0.00
-100.00%
|
1.00
|
0.00
|
| Cost Of Revenue |
|
0.38
|
0.00
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
0.38
|
0.00
|
—
|
—
|
| Gross Profit |
|
0.03
|
0.00
|
—
|
—
|
| Operating Expense |
|
13.31
+5.04%
|
12.68
+16.28%
|
10.90
-25.49%
|
14.63
|
| Research And Development |
|
7.15
-0.55%
|
7.19
+27.16%
|
5.66
-38.12%
|
9.14
|
| Selling General And Administration |
|
6.16
+12.38%
|
5.48
+4.54%
|
5.24
-4.42%
|
5.48
|
| General And Administrative Expense |
|
6.16
+12.38%
|
5.48
+4.54%
|
5.24
-4.42%
|
5.48
|
| Other Gand A |
|
6.16
+12.38%
|
5.48
+4.54%
|
5.24
-4.42%
|
5.48
|
| Total Expenses |
|
13.69
+8.03%
|
12.68
+16.28%
|
10.90
-25.49%
|
14.63
|
| Operating Income |
|
-13.28
-4.79%
|
-12.68
-28.03%
|
-9.90
+32.32%
|
-14.63
|
| Total Operating Income As Reported |
|
-13.28
-4.79%
|
-12.68
-28.03%
|
-9.90
+32.32%
|
-14.63
|
| EBITDA |
|
-13.26
-4.81%
|
-12.65
-28.08%
|
-9.88
+32.38%
|
-14.61
|
| Normalized EBITDA |
|
-13.26
-4.81%
|
-12.65
-28.08%
|
-9.88
+32.38%
|
-14.61
|
| Reconciled Depreciation |
|
0.02
-4.64%
|
0.02
+3.85%
|
0.02
+14.62%
|
0.02
|
| EBIT |
|
-13.28
-4.79%
|
-12.68
-28.03%
|
-9.90
+32.32%
|
-14.63
|
| Net Income |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Pretax Income |
|
-11.99
-8.58%
|
-11.04
-28.89%
|
-8.57
+39.08%
|
-14.07
|
| Net Non Operating Interest Income Expense |
|
1.30
-21.97%
|
1.67
-8.93%
|
1.83
+126.59%
|
0.81
|
| Net Interest Income |
|
1.30
-21.97%
|
1.67
-8.93%
|
1.83
+126.59%
|
0.81
|
| Interest Income Non Operating |
|
1.30
-21.97%
|
1.67
-8.93%
|
1.83
+126.59%
|
0.81
|
| Interest Income |
|
1.30
-21.97%
|
1.67
-8.93%
|
1.83
+126.59%
|
0.81
|
| Other Income Expense |
|
-0.01
+67.70%
|
-0.04
+92.15%
|
-0.50
-103.36%
|
-0.25
|
| Other Non Operating Income Expenses |
|
-0.01
+67.70%
|
-0.04
+92.15%
|
-0.50
-103.36%
|
-0.25
|
| Tax Provision |
|
0.01
+8.25%
|
0.01
+81.72%
|
0.00
+7.97%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Net Income From Continuing And Discontinued Operation |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Net Income Continuous Operations |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Normalized Income |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Net Income Common Stockholders |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Diluted EPS |
|
-0.24
-4.35%
|
-0.23
-35.29%
|
-0.17
+41.38%
|
-0.29
|
| Basic EPS |
|
-0.24
-4.35%
|
-0.23
-35.29%
|
-0.17
+41.38%
|
-0.29
|
| Basic Average Shares |
|
49.06
+0.04%
|
49.05
+0.00%
|
49.05
+0.00%
|
49.05
|
| Diluted Average Shares |
|
49.06
+0.04%
|
49.05
+0.00%
|
49.05
+0.00%
|
49.05
|
| Diluted NI Availto Com Stockholders |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
66.27
|
| Current Assets |
|
51.17
|
| Cash Cash Equivalents And Short Term Investments |
|
51.00
|
| Cash And Cash Equivalents |
|
51.00
|
| Other Short Term Investments |
|
0.00
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
0.17
|
| Total Non Current Assets |
|
15.10
|
| Net PPE |
|
0.62
|
| Gross PPE |
|
1.06
|
| Accumulated Depreciation |
|
-0.44
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.48
|
| Other Properties |
|
0.58
|
| Leases |
|
0.01
|
| Goodwill And Other Intangible Assets |
|
14.40
|
| Goodwill |
|
9.60
|
| Other Intangible Assets |
|
4.80
|
| Other Non Current Assets |
|
0.07
|
| Total Liabilities Net Minority Interest |
|
3.89
|
| Current Liabilities |
|
3.28
|
| Payables And Accrued Expenses |
|
2.07
|
| Payables |
|
1.00
|
| Accounts Payable |
|
1.00
|
| Current Accrued Expenses |
|
1.07
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.82
|
| Current Debt And Capital Lease Obligation |
|
0.22
|
| Current Capital Lease Obligation |
|
0.22
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Other Current Liabilities |
|
0.16
|
| Total Non Current Liabilities Net Minority Interest |
|
0.61
|
| Non Current Deferred Liabilities |
|
0.20
|
| Non Current Deferred Revenue |
|
—
|
| Non Current Deferred Taxes Liabilities |
|
0.20
|
| Other Non Current Liabilities |
|
0.41
|
| Stockholders Equity |
|
62.38
|
| Common Stock Equity |
|
62.38
|
| Capital Stock |
|
0.05
|
| Common Stock |
|
0.05
|
| Share Issued |
|
49.05
|
| Ordinary Shares Number |
|
49.05
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
478.15
|
| Retained Earnings |
|
-415.70
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.12
|
| Other Equity Adjustments |
|
-0.12
|
| Total Equity Gross Minority Interest |
|
62.38
|
| Total Capitalization |
|
62.38
|
| Working Capital |
|
47.90
|
| Invested Capital |
|
62.38
|
| Total Debt |
|
0.22
|
| Capital Lease Obligations |
|
0.22
|
| Net Tangible Assets |
|
47.98
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-9.81
+7.83%
|
-10.64
-43.22%
|
-7.43
+42.45%
|
-12.91
|
| Cash Flow From Continuing Operating Activities |
|
-9.81
+7.83%
|
-10.64
-43.22%
|
-7.43
+42.45%
|
-12.91
|
| Net Income From Continuing Operations |
|
-12.00
-8.58%
|
-11.05
-28.91%
|
-8.57
+39.08%
|
-14.07
|
| Depreciation Amortization Depletion |
|
0.02
-4.64%
|
0.02
+3.85%
|
0.02
+14.62%
|
0.02
|
| Depreciation And Amortization |
|
0.02
-4.64%
|
0.02
+3.85%
|
0.02
+14.62%
|
0.02
|
| Other Non Cash Items |
|
0.17
+0.09%
|
0.17
+214.24%
|
-0.15
-473.04%
|
0.04
|
| Stock Based Compensation |
|
0.83
-30.43%
|
1.19
+67.68%
|
0.71
+10.61%
|
0.64
|
| Operating Gains Losses |
|
—
|
-0.00
-100.04%
|
0.45
+266.91%
|
0.12
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.45
+266.53%
|
0.12
|
| Gain Loss On Sale Of PPE |
|
0.00
+100.00%
|
-0.00
-141.95%
|
0.00
|
0.00
|
| Change In Working Capital |
|
1.17
+218.93%
|
-0.98
-974.71%
|
0.11
-66.48%
|
0.33
|
| Change In Prepaid Assets |
|
0.53
+207.94%
|
-0.49
-270.71%
|
0.29
+90.98%
|
0.15
|
| Change In Payables And Accrued Expense |
|
0.46
+247.23%
|
-0.31
-1723.59%
|
0.02
-94.15%
|
0.33
|
| Change In Payable |
|
0.46
+247.23%
|
-0.31
-1723.59%
|
0.02
-94.15%
|
0.33
|
| Change In Account Payable |
|
0.46
+247.23%
|
-0.31
-1723.59%
|
0.02
-94.15%
|
0.33
|
| Change In Other Working Capital |
|
0.37
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.20
-10.67%
|
-0.18
+9.58%
|
-0.19
-33.92%
|
-0.15
|
| Investing Cash Flow |
|
-0.00
-315.93%
|
-0.00
-100.00%
|
39.91
+199.76%
|
-40.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
-315.93%
|
-0.00
-100.00%
|
39.91
+199.76%
|
-40.01
|
| Net PPE Purchase And Sale |
|
-0.00
-315.93%
|
-0.00
+96.73%
|
-0.02
-325.13%
|
-0.01
|
| Purchase Of PPE |
|
-0.00
-223.91%
|
-0.00
+95.80%
|
-0.02
-325.13%
|
-0.01
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.00
|
0.00
|
—
|
| Capital Expenditure |
|
-0.00
-223.91%
|
-0.00
+95.80%
|
-0.02
-325.13%
|
-0.01
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
39.93
+199.82%
|
-40.00
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-59.88
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
39.93
+100.88%
|
19.88
|
| Financing Cash Flow |
|
0.24
|
0.00
|
0.00
-100.00%
|
0.01
|
| Cash Flow From Continuing Financing Activities |
|
0.24
|
0.00
|
0.00
-100.00%
|
0.01
|
| Net Common Stock Issuance |
|
0.24
|
0.00
|
0.00
-100.00%
|
0.01
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-9.57
+10.10%
|
-10.64
-132.77%
|
32.48
+161.38%
|
-52.91
|
| Effect Of Exchange Rate Changes |
|
0.02
+296.29%
|
0.00
-77.09%
|
0.02
+202.75%
|
-0.02
|
| Beginning Cash Position |
|
40.36
-20.86%
|
51.00
+175.59%
|
18.51
-74.09%
|
71.43
|
| End Cash Position |
|
30.81
-23.67%
|
40.36
-20.86%
|
51.00
+175.59%
|
18.51
|
| Free Cash Flow |
|
-9.81
+7.81%
|
-10.64
-42.83%
|
-7.45
+42.30%
|
-12.92
|
| Income Tax Paid Supplemental Data |
|
0.01
+11.44%
|
0.01
+37.50%
|
0.00
|
0.00
|
| Common Stock Issuance |
|
0.24
|
0.00
|
0.00
-100.00%
|
0.01
|
| Issuance Of Capital Stock |
|
0.24
|
0.00
|
0.00
-100.00%
|
0.01
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-10 View
- 8-K2026-02-20 View
- 42026-01-20 View
- 42026-01-20 View
- 8-K2025-12-30 View
- 10-Q2025-11-12 View
- 10-Q2025-08-14 View
- 8-K2025-08-01 View
- 42025-06-20 View
- 42025-06-20 View
- 42025-06-20 View
- 8-K2025-06-18 View
- 10-Q2025-05-13 View
- 8-K2025-03-11 View
- 10-K2025-02-19 View
- 42025-02-14 View
- 42025-02-14 View
- 42025-02-14 View
- 42025-02-14 View
- 42025-02-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|